報價延遲最少15分鐘:2025/05/28 13:00 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.65 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.07/-0.03
|
|
企業價值
157.31M
|
| 資產負債 |
|
每股賬面淨值
0.35
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
8.95M
|
|
每股收益
0.05
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/05/28 13:00 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss. |